The results of this investigation provide a sound basis for the novel and exciting further investigation of cMLC-1 as a blood protein biomarker for screening breast cancer, evaluating disease progression, monitoring treatment response and predicting TIC. This evidence concerns the gene MYL3 and breast cancer.